Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Split-dose NT201 satisfaction study with doubled injection frequency
NL-OMON49792Not yet recruiting
- Sponsor
- Flack Clinic
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of incobotulinumtoxinA in facial rhytids, glabellar furrowing and Forehead lines (2 arms), sponsored by Flack Clinic. Primary endpoint: Treatment satisfaction over time. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
incobotulinumtoxinA
03
Conditions
facial rhytidsglabellar furrowingForehead lines
Beyond the preview
Go deeper on NL-OMON49792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49792.